Compositions comprising bacterial strain
The invention provides compositions comprising bacterial strains for treating and preventing cancer.
1. A pharmaceutical composition that comprises:
a lyophilized Enterococcus gallinarum bacteria strain deposited under NCIMB 42761; and
a pharmaceutically acceptable excipient, diluent, or carrier.
2. The pharmaceutical composition of claim 1 , wherein the lyophilized Enterococcus gallinarum bacteria strain is present in an amount of at least 1×10 3 CFU/g of the lyophilized Enterococcus gallinarum bacteria strain with respect to a total weight of the pharmaceutical composition.
3. The pharmaceutical composition of claim 1 , wherein the lyophilized Enterococcus gallinarum bacteria strain is present in an amount of from about 1×10 6 to about 1×10 11 CFU/g of the lyophilized Enterococcus gallinarum bacteria strain with respect to a total weight of the pharmaceutical composition.
4. The pharmaceutical composition of claim 1 , further comprising a lipopolysaccharide.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral delivery.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for rectal delivery.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises an enteric coating.
8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a solid dose composition.
9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition only contains the lyophilized Enterococcus gallinarum bacteria strain and the pharmaceutically acceptable excipient, diluent, or carrier.
10. The pharmaceutical composition of claim 1 , wherein the lyophilized Enterococcus gallinarum bacteria strain is live.
11. A vaccine comprising the pharmaceutical composition of claim 1 .
12. A method of treating a cancer in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition that comprises Enterococcus gallinarum bacteria strain deposited under NCIMB 42761.
13. The method of claim 12 , wherein the Enterococcus gallinarum bacteria strain is lyophilized.
14. The method of claim 12 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, diluent, or carrier.
15. The method of claim 12 , wherein the cancer is a solid tumor cancer.
16. The method of claim 12 , wherein the cancer is a lung, liver, colon, breast, ovarian, prostate, pancreatic, testicular, thyroid, renal, gallbladder, or gastric cancer.
17. The method of claim 16 , wherein the cancer is a breast cancer, and wherein the breast cancer is mammary carcinoma or stage IV breast cancer.
18. The method of claim 12 , wherein the Enterococcus gallinarum bacteria strain is live.
19. The method of claim 12 , wherein the pharmaceutical composition comprises an enteric coating.
20. The method of claim 12 , wherein the subject has cancer.
21. The method of claim 12 , wherein the subject has previously received treatment for cancer.
22. The method of claim 12 , wherein the therapeutically effective amount comprises at least 1×10 3 CFU/g of the Enterococcus gallinarum bacteria strain with respect to a total weight of the pharmaceutical composition.
23. The method of claim 12 , wherein the therapeutically effective amount comprises from about 1×10 6 to about 1×10 11 CFU/g of the Enterococcus gallinarum bacteria strain with respect to a total weight of the pharmaceutical composition.
24. The method of claim 12 , wherein the administering is an oral administering.
25. The method of claim 12 , wherein the administering is a rectal administering.